Participated · Series B · Oct 2019

Tmunity Therapeutics is a clinical‑stage biotherapeutics company focused on delivering next‑generation T‑cell immunotherapy for cancer and other devastating diseases. The company integrates scientific, clinical and manufacturing expertise from its founders and collaborators to develop engineered T‑cell constructs. Tmunity has a diversified portfolio with three programs currently in clinic development and a pipeline aiming at both solid and liquid tumors. It operates laboratories and production facilities at the University of Pennsylvania and a dedicated cGMP manufacturing facility in East Norriton, PA, and collaborates with the Parker Institute, UCSF and Children’s Hospital of Philadelphia. The company emphasizes process improvement and production scale‑up to support clinical development and eventual commercialization. Tmunity’s leadership includes founders with prior CAR‑T experience and executives who helped bring the first CAR‑T therapy to market. Tmunity Therapeutics is a private clinical‑stage biotherapeutics company focused on delivering next‑generation T cell immunotherapy to patients with cancer, infectious disease and autoimmune disease. The company is developing a diversified portfolio of personalized T cell–based therapies designed to exert best‑in‑class control over T cell activation and direction in the body. Tmunity was founded on an exclusive collaboration and license agreement with the University of Pennsylvania and cites Carl H. June, M.D. among its scientific founders. It leverages laboratories and production facilities at UPenn and operates a dedicated cGMP manufacturing facility in Norristown, PA to pursue process improvement and scale production. The company aims to translate multiple engineered T cell approaches rapidly into the clinic, optimize manufacturing and pursue regulatory approvals. Its recent financing is intended to expand the business and operational structure to support development and manufacture of its portfolio. Tmunity Therapeutics develops engineered T cell therapies and platforms aimed at freeing the immunological potential of T cells to treat a wide range of disease indications. Its product focus includes T cell receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that provide control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood, and tumors. Tmunity intends to use newly raised funds to advance development of these novel products. The company was co-founded by Anne Chew, Carl H. June, Bruce Levine, James L. Riley, Yangbing Zhao, and Bruce Blazar, who hold roles at Penn and the University of Minnesota. Tmunity is based in Philadelphia, PA.

Participated · Series C · Apr 2018

Magenta Therapeutics is developing an integrated portfolio of novel therapeutics to address unmet needs in bone marrow transplantation, including targeted transplant conditioning, stem cell mobilization, and stem cell expansion programs. The company’s most advanced clinical product candidate, MGTA-456, is a cell therapy currently in a Phase 2 trial for patients with inherited metabolic diseases. Magenta says it will use the proceeds from the financing to advance its portfolio and further develop MGTA-456. The company was launched in 2016 by Third Rock Ventures and Atlas Venture. Jason Gardner, D.Phil., is the company’s chief executive officer, president and co‑founder. Magenta’s programs target patients with autoimmune diseases, blood cancers and genetic diseases. Magenta Therapeutics is a Cambridge, Mass.-based biotechnology company that develops therapeutics leveraging stem cell biology and bone marrow transplant to reboot the immune and blood systems. The company is developing treatments aimed at autoimmune diseases, genetic blood disorders and cancer. Through a license agreement with Harvard University, Magenta has access to a portfolio of stem cell technologies developed at Harvard, Massachusetts General Hospital and Boston Children’s Hospital. Its leadership includes CEO and cofounder Jason Gardner, D. Phil., CSO Michael Cooke, Ph.D., COO Bastiano Sanna, Ph.D., and VP Christina Isacson, Ph.D. Magenta was founded by recognized stem cell experts including David Scadden, Derrick Rossi, John Dipersio, Robert Negrin, Luigi Naldini and Alan Tyndall. Magenta completed a $48.5M Series A financing to advance its programs.